author-photo

Caroline Decker

Vertex Pharmaceuticals

17

Papers

2642

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator

2014 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (61)
Corrigendum to “Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists” [Bioorg. Med. Chem. Lett. 24 (2014) 845–849]

2014 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (0)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

2011 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (813)
Efficient Screening of Cytochrome P450 BM3 Mutants for Their Metabolic Activity and Diversity toward a Wide Set of Drug-Like Molecules in Chemical Space

2011 Drug Metabolism and Disposition
Show All
- Source
- Cite
- Save
Citations (33)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

2009 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (888)
(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18

2007 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (161)
Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor

2002 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (29)
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.

2001 Drugs Under Experimental and Clinical Research
Show All
- Source
- Cite
- Save
Citations (8)
VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival

1999 Journal of Heart and Lung Transplantation
Show All
- Source
- Cite
- Save
Citations (4)
The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival

1999 Transplantation
Show All
- Source
- Cite
- Save
Citations (3)